Darren "Ben" Finlay, Ph.D.

Finlay

Darren "Ben" Finlay, Ph.D.

Research Assistant Professor
Scientific Director

Darren "Ben" Finlay's Research Focus

Brain Cancer, Breast Cancer, Pancreatic Cancer, Skin Cancer and Melanoma, Leukemia/Lymphoma, Lung Cancer

Dr. Finlay's research is focused on apoptosis (programmed cell death) and how this process can be manipulated to kill cancer cells.

Darren "Ben" Finlay's Bio

Education

University College Dublin
B.Sc. and Ph.D., Pharmacology, cell and molecular biology, signal transduction and cancer, First Class Honors

 


general accessory

Publications

Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.

Finlay D, Richardson RD, Landberg LK, Howes AL, Vuori K

PLoS One 2010 Oct 12 ;5(10):e13375

Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines.

Cipres A, O'Malley DP, Li K, Finlay D, Baran PS, Vuori K

ACS Chem Biol 2010 Feb 19 ;5(2):195-202

Caspase-8 as a potential mediator of pro-tumorigenic signals.

Finlay D, Howes A, Vuori K

Cell Cycle 2009 Nov 1 ;8(21):3441-2

Show All Select Publications

Cell adhesion suppresses autophagy via Src/FAK-mediated phosphorylation and inhibition of AMPK.

Zhao M, Finlay D, Kwong E, Liddington R, Viollet B, Sasaoka N, Vuori K

Cell Signal 2021 Oct 18 ;89:110170

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, Fabre B, Li Y, Fujita Y, Zhang T, Yin J, Pass I, Livneh I, Jeremias I, Burian C, Mason JR, Almog R, Horesh N, Ofran Y, Brown K, Vuori K, Jackson M, Ruppin E, Deshpande AJ, Ronai ZA

Nat Commun 2021 Sep 13 ;12(1):5397

PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.

Benitez JA, Finlay D, Castanza A, Parisian AD, Ma J, Longobardi C, Campos A, Vadla R, Izurieta A, Scerra G, Koga T, Long T, Chavez L, Mesirov JP, Vuori K, Furnari F

Neuro Oncol 2021 Jul 1 ;23(7):1072-1086

FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.

Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C

Cell 2021 Jan 21 ;184(2):352-369.e23

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.

Rusert JM, Juarez EF, Brabetz S, Jensen J, Garancher A, Chau LQ, Tacheva-Grigorova SK, Wahab S, Udaka YT, Finlay D, Seker-Cin H, Reardon B, Gröbner S, Serrano J, Ecker J, Qi L, Kogiso M, Du Y, Baxter PA, Henderson JJ, Berens ME, Vuori K, Milde T, Cho YJ, Li XN, Olson JM, Reyes I, Snuderl M, Wong TC, Dimmock DP, Nahas SA, Malicki D, Crawford JR, Levy ML, Van Allen EM, Pfister SM, Tamayo P, Kool M, Mesirov JP, Wechsler-Reya RJ

Cancer Res 2020 Dec 1 ;80(23):5393-5407

MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.

Lee B, Sahoo A, Sawada J, Marchica J, Sahoo S, Layng FIAL, Finlay D, Mazar J, Joshi P, Komatsu M, Vuori K, de Jong PR, Ray A, Perera RJ

J Invest Dermatol 2021 Feb ;141(2):385-394

Show All Publications